Literature DB >> 15710122

Views of UK melanoma patients on routine follow-up care.

A Dancey1, S Rayatt, J Courthold, J Roberts.   

Abstract

Although the need for melanoma follow-up is universally accepted, there is still much debate on the duration and frequency of appointments. The UK guidelines were revised in June 2002 to streamline melanoma follow-up. Following the change in protocol, some of our patients expressed concern at the shorter duration of follow-up. We therefore polled all our active melanoma patients to obtain their views on the outpatient clinics. In particular we asked whether they would be happy to have routine follow-up in a primary care setting. In conjunction with the department of psychology, a short questionnaire was devised assessing patient satisfaction and concerns about follow-up. This was sent to all active melanoma patients in our trust. Out of 304 eligible patients currently attending outpatients, 231 (76%) completed replies were received. Ninety-eight percent of respondents found the clinics to be useful. Twenty two and a half percent felt it was difficult to attend the clinic and this was mainly due to logistical problems, i.e. hospital car parking. The majority were reassured by the clinic visits and felt it was a chance to ask questions and check for new disease. Of the 12% of respondents who had a recurrence, 52% indicated that they had detected it themselves. Sixty percent of patients would be happy to consider routine follow-up with their GP, provided they were suitably experienced and trained. A survey of 50 local GP's found that 70% would be unhappy to monitor their patients. Patients want and benefit from follow-up. However, they are an increasing burden on outpatient clinics, given the increasing incidence of melanoma. GP follow-up may be appropriate for a small subgroup of patients. This combined with shared care and practice based clinical nurse specialists may be the way forward in melanoma follow-up.

Entities:  

Mesh:

Year:  2005        PMID: 15710122     DOI: 10.1016/j.bjps.2004.10.012

Source DB:  PubMed          Journal:  Br J Plast Surg        ISSN: 0007-1226


  7 in total

1.  Follow-up care for young adult survivors of cancer: lessons from pediatrics.

Authors:  Christine Eiser; Kate Absolom; Diana Greenfield; John Snowden; Robert Coleman; Barry Hancock; Helena Davies
Journal:  J Cancer Surviv       Date:  2007-03       Impact factor: 4.442

2.  Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial.

Authors:  P Murchie; M C Nicolson; P C Hannaford; E A Raja; A J Lee; N C Campbell
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

3.  Follow-up care for cancer survivors: views of the younger adult.

Authors:  K Absolom; C Eiser; G Michel; S J Walters; B W Hancock; R E Coleman; J A Snowden; D M Greenfield
Journal:  Br J Cancer       Date:  2009-07-28       Impact factor: 7.640

4.  GP-led melanoma follow-up: views and feelings of patient recipients.

Authors:  Peter Murchie; Elizabeth K Delaney; Neil C Campbell; Philip C Hannaford
Journal:  Support Care Cancer       Date:  2009-05-10       Impact factor: 3.603

5.  Family doctor-driven follow-up for adult childhood cancer survivors supported by a web-based survivor care plan.

Authors:  R Blaauwbroek; H A Barf; K H Groenier; L C Kremer; K van der Meer; W J E Tissing; A Postma
Journal:  J Cancer Surviv       Date:  2011-11-29       Impact factor: 4.442

6.  Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians' perspectives and models of care.

Authors:  Lucie Rychetnik; Rachael L Morton; Kirsten McCaffery; John F Thompson; Scott W Menzies; Les Irwig
Journal:  BMC Health Serv Res       Date:  2012-12-19       Impact factor: 2.655

7.  Various Dermatoses What the Patients with Cutaneous Melanoma Had Anxiety for the Recurrence during Postoperative Surveillance.

Authors:  Hyun-Joo Lee; Hyunju Jin; Hyang-Suk You; Woo-Haing Shim; Jeong-Min Kim; Gun-Wook Kim; Je-Ho Mun; Hoon-Soo Kim; Hyun-Chang Ko; Byung-Soo Kim; Moon-Bum Kim
Journal:  Ann Dermatol       Date:  2017-06-21       Impact factor: 1.444

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.